Loading financials from SEC filings…
Biotechnology · Healthcare · Fiscal year ends Mar 31
Net income was −$314M. Operating cash flow of −$280M less capital expenditure of $4M left free cash flow of −$285M. It held more cash than debt (net cash $126M).
Last 5 fiscal years
| Fiscal year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Research & development | 79.5 | 127 | 175 | 189 | 221 |
| Selling, general & admin | – | – | – | 72.2 | 98.7 |
| Operating income | −118 | −177 | −235 | −262 | −320 |
| Interest expense | 0.0 | 2.0 | 4.5 | 5.8 | 6.8 |
| Pre-tax income | −118 | −174 | −215 | −247 | −314 |
| Income tax | 0.0 | 0.3 | 0.4 | 0.5 | −0.6 |
| Net income | −118 | −174 | −216 | −247 | −314 |
| Diluted EPS | −2.26 | −2.99 | −3.24 | −3.07 | −3.38 |
| Diluted shares | 52.2 | 58.2 | 66.6 | 80.6 | 92.8 |
| Fiscal year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Cash & equivalents | 106 | 147 | 74.5 | 111 | 209 |
| Inventory | – | – | – | – | 0.0 |
| Current assets | 404 | 593 | 434 | 496 | 279 |
| Net PP&E | 7.9 | 7.5 | 10.5 | 13.7 | 13.0 |
| Total assets | 461 | 647 | 488 | 551 | 332 |
| Payables | 3.7 | 5.4 | 2.6 | 12.5 | 6.7 |
| Current liabilities | 20.8 | 33.8 | 40.4 | 62.4 | 58.2 |
| Long-term debt | 0.0 | 28.6 | 44.8 | 46.4 | 83.3 |
| Total liabilities | 50.0 | 91.3 | 113 | 135 | 166 |
| Shareholders' equity | 411 | 555 | 375 | 416 | 166 |
| Fiscal year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating cash flow | −82.2 | −128 | −185 | −192 | −280 |
| Capital expenditure | 2.3 | 2.3 | 5.7 | 6.7 | 4.2 |
| Free cash flow | −84.5 | −130 | −191 | −199 | −285 |
| Depreciation & amortisation | 2.1 | 2.4 | 2.7 | 3.5 | 3.3 |
| Stock-based compensation | 24.3 | 28.1 | 34.1 | 35.0 | 32.3 |
| Fiscal year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Return on equityBlank when equity is negative | −28.7% | −31.4% | −57.6% | −59.5% | −188.9% |
| ROCEEBIT ÷ (assets − current liabilities) | −26.9% | −28.9% | −52.5% | −53.5% | −116.7% |
| Cash conversion (CFO ÷ net income) | 0.70x | 0.73x | 0.86x | 0.78x | 0.89x |
| Interest cover | – | −90.2x | −52.2x | −45.3x | −47.1x |
| Debt ÷ equity | 0.00x | 0.05x | 0.12x | 0.11x | 0.50x |
| Net debtDebt − cash & equivalents; excludes investments; negative = net cash | −106 | −118 | −29.6 | −64.7 | −126 |
| Current ratio | 19.5x | 17.5x | 10.7x | 7.95x | 4.79x |
Standardised figures from the company's XBRL filings with the SEC (10-K, 10-Q). Line items follow US GAAP tags, so a company's own statement layout may differ and some lines show “–” where the company does not report that item. Ratios are calculated from these figures. For education only; not investment advice or a recommendation.